| Code | 1696F | ||||||||||
| MA number | 21/0340/25-S | ||||||||||
| Product Form: | tbl flm 100x1x75 mg (blis.OPA/Al/PVC/Al-jednotk.bal.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Glenmark Pharmaceuticals s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister OPA/Al/PVC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 20.10.2025 |
| Validity: | 20.10.2030 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| PIL: |
PIL_Brivaracetam Glenmark 10_25_50_75_100 mg_tbl flm_10_2025_REG.pdf
|
| SPC: |
SPC_Brivaracetam Glenmark 10_25_50_75_100 mg_tbl flm_10_2025_REG.pdf
|
| Safety feature | Yes |
| Data update: | 22.10.2025 |
